Targeted Delivery of Circular Single‐Stranded DNA Encoding IL‐12 for the Treatment of Triple‐Negative Breast Cancer
Advanced Healthcare Materials · 2024
DOI: 10.1002/adhm.202401376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2024. Verfasst von Yijing Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Tianjin University, Tianjin, 300072, China. Hauptthemen laut MEDLINE: Interleukin-12, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Leading Health Talents in Zhejiang Province.
Abstract (Originalsprache)
Interleukin‐12 (IL‐12) is a critical cytokine with notable anticancer properties, including enhancing T‐cell‐mediated cancer cell killing, and curbing tumor angiogenesis. To date, many approaches are evaluated to achieve in situ overexpression of IL‐12, minimizing leakage and the ensuing toxicity. Here, it is focused on circular single‐stranded DNA (Css DNA), a type of DNA characterized by its unique structure, which could be expressed in mammals. It is discovered that Css DNA can induce sustained luciferase expression for half a year by intramuscular injection and showed effective antitumor results by intratumoral injection. Motivated by these findings, a folate‐modified LNP system is now developed for the delivery of Css DNA expressing IL‐12 for the therapy of 4T1 triple‐negative breast cancer (TNBC). This delivery system effectively activates anti‐cancer immune responses, slows tumor growth, significantly prolongs survival in animal models, and prevents tumor recurrence. After 6 months of long‐term observation, the elevated level of IL‐12 is still detectable in the lymph nodes and serum of the cured mice. This study highlights the long‐term sustained expression capacity of Css DNA and its ability to inhibit recurrence, and the potential of tumor‐targeted LNPs for Css DNA‐based cancer therapy, providing a new insight into gene overexpression strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Tianjin University, Tianjin, 300072, China.
- Hangzhou Institute of Medicine, Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.
- Institute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, School of Electronic Information and Electrical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China.
- School of Biomedical Sciences, Hunan University, Changsha, Hunan, 410082, China.
ORCID-Profile: Jie Song
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Leading Health Talents in Zhejiang Province
- Natural Science Foundation of Zhejiang Province
- Youth CrossTeam Project of the Chinese Academy of Sciences
Zitieren
APA
Zhang, Y., Cao, X., Hu, G., Ye, R., Zhang, L., & Song, J. (2024). Targeted Delivery of Circular Single‐Stranded DNA Encoding IL‐12 for the Treatment of Triple‐Negative Breast Cancer. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202401376
Vancouver
Zhang Y, Cao X, Hu G, Ye R, Zhang L, Song J. Targeted Delivery of Circular Single‐Stranded DNA Encoding IL‐12 for the Treatment of Triple‐Negative Breast Cancer. Advanced Healthcare Materials. 2024. doi:10.1002/adhm.202401376
BibTeX
@article{Zhang2024,
author = {Zhang, Yijing and Cao, Xisen and Hu, Guang and Ye, Rui and Zhang, Li and Song, Jie},
title = {Targeted Delivery of Circular Single‐Stranded DNA Encoding IL‐12 for the Treatment of Triple‐Negative Breast Cancer},
journal = {Advanced Healthcare Materials},
year = {2024},
doi = {10.1002/adhm.202401376}
}
EUVIMED